Abstract:Rationale: With the advancement of targeted therapies, epidermal growth factor receptor tyrosine kinase inhibitors have become the preferred initial treatment for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is effective against exon 19 and 21 mutations as well as the T790M mutation. It has been approved by both the food and drug administration and European Medicines Agency for the treatment of non-small cell lung cancer patients with locally advanced or metastatic EGFR-mutated tumors, including those who have acquired T790M mutations. Patient concerns: To evaluate the effectiveness of osimertinib in treating patients with EGFR-mutated advanced lung adenocarcinoma and bone metastases, we present the treatment outcomes of 3 patients with EGFR 19 deletion-mutated advanced lung adenocarcinoma and bone metastases who received osimertinib treatment in recent years. All 3 cases involved elderly female patients, aged 62, 62, and 54, respectively. Diagnoses: All 3 cases exhibited a diagnosis of pulmonary adenocarcinoma accompanied by osseous metastases, with genetic testing revealing the presence of an EGFR 19del mutation. Interventions: In the first case, following 17 months of gefitinib therapy, disease progression prompted a switch to osimertinib treatment. In the second case, bone metastases were detected after 20 months of pemetrexed-carboplatin chemotherapy, leading to a transition to osimertinib therapy. In the third case, after 11 months of erlotinib treatment, bone metastases were identified. Subsequent interventions, including radiation therapy, pemetrexed-carboplatin chemotherapy, pemetrexed-bevacizumab maintenance therapy, and docetaxel chemotherapy, failed to arrest the progression of bone metastases. As a result, a combination of osimertinib and anlotinib targeted therapy was administered. Outcomes: All 3 patients experienced relatively good and favorable survival outcomes, with a progression-free survival of 22.7 months, 12 months, and 17.7 months, respectively. Lessons: These cases suggest that osimertinib is a promising treatment option for patients with EGFR 19 deletion-mutated lung adenocarcinoma and bone metastases, although further clinical studies are needed to confirm its efficacy.

Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review

Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report

An Advanced Non-Small Cell Lung Cancer Patient with Epidermal Growth Factor Receptor Sensitizing Mutation Responded to Toripalimab in Combination with Chemotherapy after Resistance to Osimertinib: a Case Report

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series

Successful Treatment of EGFR T790M-mutant Non-Small Cell Lung Cancer with Almonertinib after Osimertinib-Induced Interstitial Lung Disease: a Case Report and Literature Review

A Consensus on the Role of Osimertinib in Non-Small Cell Lung Cancer from the AME Lung Cancer Collaborative Group

An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer

Significant Benefits of Osimertinib in Treating Acquired Resistance to First-Generation EGFR-TKIs in Lung Squamous Cell Cancer: A Case Report.

A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study

Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature

Durable Response to Osimertinib in an Advanced Lung Adenocarcinoma Patient with an Uncommon EGFR T854A Mutation: A Case Report

First-line Treatment of EGFR Mutation Adenosquamous Carcinoma of the Lung with Aumolertinib: A Multicenter, Single-Arm, Prospective Study (ARISE Study).

A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma

Aumolertinib: A Review in Non-Small Cell Lung Cancer

Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report

Efficacy and Safety of Aumolertinib Combined with or Without Chemotherapy As an Adjuvant Treatment for Stage II-IIIA Non-Small Cell Lung Cancer Following Complete Tumour Resection: the First Third-Generation EGFR-TKI Versus Chemotherapy Phase III Clinical Study (APEX).

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (<i>EGFR</i>-TKI) in <i>EGFR</i>-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients

The Patient Outcomes with EGFR-mutated Advanced Non-Small-cell Lung Cancer Receiving Aumolertinib As First-Line Treatment.